—ORLADEYO net revenue of $90.9 million for Q4 2023 and $326.0 million for FY 2023 (+30 percent y-o-y) — —2024 ORLADEYO net revenue expected to be between $380-$400 million— —Company expects operating profit in 2024, approaching positive EPS and positive cash flow in 2H 2025— RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. ...

RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat) that showed patients who initiated ORLADEYO experienced rapid, substantial and sustained reductions in attack rates through 18 months of treatment regardless of the severity of their disease, their history of prior prophylaxis or their C1-inhibitor (C1-INH) level and function. The data are being presented in ...

RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the TD Cowen 44th Annual Health Care Conference in Boston on Wednesday, March 6, 2024, at 10:30 a.m. ET and the Barclays 26th Annual Global Healthcare Conference in Miami on Tuesday, March 12, 2024, at 7:30 a.m. ET. Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst's website ...

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Italy now have access to the first oral, once-daily therapy for the routine prevent ...

RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2023 financial results on Monday, February 26, 2024. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webca ...

RESEARCH TRIANGLE PARK, N.C. , Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. The meeting will take place at the Walter E. Washington Convention Center in ...

Core Insights - BioCryst Pharmaceuticals will present five abstracts on the real-world use of ORLADEYO® (berotralstat) for hereditary angioedema (HAE) at the 2024 AAAAI annual meeting [1] - ORLADEYO is the first oral therapy specifically designed to prevent HAE attacks in patients aged 12 and older [2][3] Group 1: Abstract Presentations - The first abstract discusses how berotralstat prophylaxis reduces HAE attack rates regardless of baseline attacks [1] - The second abstract highlights consistently low HAE attack rates with berotralstat, irrespective of prior prophylaxis [1] - The third abstract presents interim analysis from the Berolife Study on the tolerability and effectiveness of berotralstat for long-term prophylaxis [1] - The fourth abstract evaluates adherence to berotralstat through a prospective survey in community pharmacies [1] - The fifth abstract assesses the real-world effectiveness of berotralstat in HAE patients with and without C1-inhibitor deficiency [1] Group 2: Product Information - ORLADEYO is indicated for the prophylaxis of HAE attacks in adults and pediatric patients aged 12 years and older [3] - The drug works by decreasing the activity of plasma kallikrein, preventing HAE attacks with a once-daily capsule [2] - Safety information indicates that the effectiveness of ORLADEYO for acute HAE attacks has not been established, and it should not be used for such treatment [4] Group 3: Safety and Efficacy - Common adverse reactions in patients receiving ORLADEYO include abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease [5] - A reduced dosage of 110 mg is recommended for patients with moderate or severe hepatic impairment [5] - The drug is a moderate inhibitor of CYP2D6 and CYP3A4, necessitating monitoring for concomitant medications [6]

Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of individuals with complement-mediated and other rare diseases [3] - The company specializes in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics targeting difficult-to-treat diseases [3] - BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies [3] Stock Options and RSUs Grant - BioCryst's board of directors granted stock options to nine newly-hired employees, allowing them to purchase a total of 32,100 shares, along with restricted stock units (RSUs) covering 21,450 shares [1] - The options have an exercise price of $5.30 per share, equal to the closing price of BioCryst common stock on the grant date [2] - The options and RSUs will vest in four equal annual installments starting on the one-year anniversary of the grant date, contingent on the employees' continued service with the company [2]

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock BCRX Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants John Bluth - Investor Relations Jon Stonehouse - Chief Executive Officer Charlie Gayer - Chief Commercial Officer Jinky Rosselli - Chief Data & Insights Officer Anthony Doyle - Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Stacy Ku - Cowen & Co. Liisa Bayko - Evercore ISI Serge Belanger - Needham & Company Operator Good morning and welcome to th ...